Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

[1]  Francine E. Garrett-Bakelman,et al.  Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. , 2018, Cancer cell.

[2]  H. Döhner,et al.  Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens , 2017, BMC Cancer.

[3]  W. Frankel,et al.  Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. , 2017 .

[4]  T. Haferlach,et al.  The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases , 2017, Leukemia.

[5]  Lars Bullinger,et al.  Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[7]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[8]  Rashmi Kanagal-Shamanna,et al.  TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes , 2016, Cancer.

[9]  Y. Chung,et al.  Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome , 2016, Oncotarget.

[10]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[11]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[12]  H. Kestler,et al.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features , 2016, Leukemia.

[13]  D. Grimwade,et al.  Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.

[14]  B. Ko,et al.  Genetic alterations and their clinical implications in older patients with acute myeloid leukemia , 2016, Leukemia.

[15]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[16]  Christopher Gandrud,et al.  simPH: An R package for illustrating estimates from cox proportional hazard models including for interactive and nonlinear effects , 2015 .

[17]  Peter P. Wakker,et al.  MF Calculator: A Web-Based Application for Analyzing Similarity , 2015 .

[18]  J. Merker,et al.  Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations , 2015, Modern Pathology.

[19]  D. Birnbaum,et al.  Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes , 2015, Oncotarget.

[20]  L. Pleyer,et al.  Digging deep into “dirty” drugs – modulation of the methylation machinery , 2015, Drug metabolism reviews.

[21]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[22]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[23]  B. Johansson,et al.  Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience , 2014, Blood Cancer Journal.

[24]  H. Kantarjian,et al.  Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. , 2011, Clinical lymphoma, myeloma & leukemia.

[25]  R. B. Richardson.  p53 mutations associated with aging-related rise in cancer incidence rates , 2013, Cell cycle.

[26]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[27]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[28]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[29]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[30]  Ombretta Annibali,et al.  Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. , 2011, Critical reviews in oncology/hematology.

[31]  Yong-mei Zhu,et al.  Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. , 2011, Blood.

[32]  T. Haferlach,et al.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. , 2011, Blood.

[33]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[34]  T. Haferlach,et al.  Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML , 2010, Leukemia.

[35]  Helen Brady,et al.  A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.

[36]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[37]  J. Issa,et al.  Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities , 2009, Cancer.

[38]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[39]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[40]  T. Haferlach,et al.  Implications of NRAS mutations in AML: a study of 2502 patients. , 2006, Blood.

[41]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[42]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[43]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[44]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[45]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.